Interferon-α influences tryptophan metabolism without inducing psychiatric side effects

Neuropsychobiology

Volumn 55, Issue 3-4, 2007, Pages 225-231

  Bannink, Marjolein ^a   Fekkes, Durk ^a   Van Gool, Arthur R ^a   Kruit, Wim H J ^a   Sleijfer, Stefan ^a   Van Der Holt, Bronno ^a   Eggermont, Alexander M M ^a   Stoter, Gerrit ^a   Hengeveld, Michiel W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Depression; Interferon ; Irritability; Mood disorders; Tryptophan metabolism

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON; TRYPTOPHAN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MENTAL PATIENT; MOOD DISORDER; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROTEIN METABOLISM; PSYCHOLOGICAL RATING SCALE; PSYCHOMETRY; SAMPLE SIZE; SELF REPORT; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; BEHAVIORAL SYMPTOMS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; MALE; MELANOMA; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; STATISTICS, NONPARAMETRIC; TIME FACTORS; TRYPTOPHAN;

EID: 34948897074     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000108382     Document Type: Article

References (25)

1. Dieperink E, Willenbring M, Ho SB: Neuropsychiatric symptoms associated with hepatitis C and interferon-α: a review. Am J Psychiatry 2000;157:867-876.
2. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff CB, Miller AH: Paroxetine for the prevention of depression induced by high-dose interferon-α. N Engl J Med 2001;344:961-966.
3. Van Gool AR, Kruit WHJ, Engels FK, Stoter G, Bannink M, Eggermont AMM: Neuropsychiatric side effects of interferon-α therapy. Pharm World Sci 2003;25:11-20.
4. Loftis JM, Hauser P: The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004;82:175-190.
5. Wichers MC, Koek GH, Robaeys G, Verkerk R, ScharpéS, Maes M: IDO and interferon-α-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005;10:538-544.
6. Hirschfeld RM: History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 2000;61(suppl 6):4-6.
7. Nemeroff CB: Recent advances in the neurobiology of depression. Psychopharmacol Bull 2002;36(suppl 2):6-23.
8. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R: Association between serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002;7:468-473.
9. Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Verkerk R, Meltzer H, Maes M: Increased depressive ratings in patients with hepatitis C receiving interferon-α-based immunotherapy are related to interferon-α-induced changes in the serotonergic system. J Clin Psychopharmacol 2002;22:86-90.
10. Van Gool AR, Fekkes D, Kruit WHJ, Mulder PGH, Ten Hagen TLM, Bannink M, Maes M, Eggermont AMM: Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-α in high-risk melanoma patients. Psychiatry Res 2003;119:125-132.
11. Van Gool AR, van Ojik HH, Kruit WHJ, Bannink M, Mulder PGH, Eggermont AMM, Stoter G, Fekkes D: Pegylated interferon-α-2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations. Anticancer Drugs 2004;15:587-591.
12. Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D, Miller AH: Interferon-α-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol Psychiatry 2003;54:906-914.
13. Myint AM, Kim YK: Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med Hypothesis 2003;61:519-525.
14. Kraus MR, Schäfer A, Csef H, Scheurlen M: Psychiatric side effects of pegylated interferon-α-2b as compared to conventional interferon-α-2b in patients with chronic hepatitis C. World J Gastroenterol 2005;11:1769-1774.
15. Russo S, Kema IP, Haagsma EB, Boon JC, Willemse PHB, den Boer JA, de Vries EGE, Korf J: Irritability rather than depression during interferon treatment is linked to increased tryptophan catabolism;in Russo S: The Tryptophan Link to Psychopathology; thesis, Groningen, 2004.
16. Derogatis LR, Cleary PA: Confirmation of the dimensional structure of the SCL-90: a study in construct validity. J Cons Psychol 1977;33:981-989.
17. Tyrer P, Owen RT, Cicchetti DV: The brief scale for anxiety: a subdivision of the comprehensive psychopathological rating scale. J Neurol Neurosurg Psychiatry 1984;4:970-975.
18. Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
19. Arrindell WA, Ettema H: Handleiding bij een Multidimensionele Psychopathologie-Indicator. Lisse, Swets & Zeitlinger, 2003.
20. Fekkes D, van Dalen A, Edelman M, Voskuilen AJ: Validation of the determination of amino acids in plasma by high-performance liquid chromatography using automated derivatisation with o-phthaldialdehyde. J Chromatogr B Biomed Appl 1995;669:177-186.
21. Borgdorff P, Fekkes D, Tangelder GJ: Hypotension caused by extracorporeal circulation: serotonin from pump-activated platelets triggers nitric oxide release. Circulation 2002;106:2588-2593.
22. Hoekstra R, van den Broek WW, Fekkes D, Bruijn JA, Mulder PGM, Pepplinkhuizen L: Effect of electroconvulsive therapy on biopterin and large neutral amino acids in severe medication-resistant depression. Psychiatry Res 2001;103:115-123.
23. Bannink M, Kruit WHJ, Van Gool AR, Sleijfer S, van der Holt B, Eggermont AMM, Stoter G, Hengeveld MW: Interferon-α in oncology patients: fewer psychiatric side effects than anticipated. Psychosomatics, in press.
24. Smith KA, Fairburn CG, Cowen PJ: Relapse of depression after rapid depletion of tryptophan. Lancet 1997;349:915-919.
25. Booij L, van der Does W, Benkelfat C, Bremner D, Cowen PJ, Fava M, Gillin C, Leyton M, Moore P, Smith KA, van der Kloot WA: Predictors of mood response to acute tryptophan depletion: a reanalysis. Neuropsychopharmacology 2002;27:853-861.